Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.
View Top Employees from Modus Therapeutics AB| Website | https://www.modustx.com/ |
| Revenue | $5.3 million |
| Employees | View employees |
| Founded | 2011 |
| Address | 117 St Eriksgatan, Stockholm, Stockholm 113 43, SE |
| Phone | +46 8 501 370 00 |
| Industry | Biotechnology Research, Business Services General, Clinical Trials, Business Services, Health Care, Pharmaceutical, Therapeutics |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies |
Looking for a particular Modus Therapeutics AB employee's phone or email?
Modus Therapeutics AB Questions
The Modus Therapeutics AB annual revenue was $5.3 million in 2024.
Modus Therapeutics AB is based in Stockholm, Stockholm.
The NAICS codes for Modus Therapeutics AB are [541714, 5417, 541, 54171, 54].
The SIC codes for Modus Therapeutics AB are [87, 873].
